YYYufeng Yang

Yufeng Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yufeng Yang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Juntong Liu

    Liaoning University of Traditional Chinese Medicine, Shenyang, China

    3 shared publications
  • Ying Zhou

    First Clinical School Liaoning University of Traditional Chinese Medicine Shenyang China

    3 shared publications
  • Juntong Liu

    Teaching and Experimental Center Liaoning University of Traditional Chinese Medicine Shenyang China

    2 shared publications
  • Mosi Dong

    Department of First Clinical School, Liaoning University of Traditional Chinese Medicine, Shenyang, China

    2 shared publications
  • Naifei Guo

    Department of Liaoning Key Laboratory of Chinese Medicine Combining Disease and Syndrome of Diabetes, Liaoning University of Traditional Chinese Medicine, Shenyang, China

    2 shared publications
  • Ruodi Yang

    First Clinical School Liaoning University of Traditional Chinese Medicine Shenyang China

    2 shared publications

Latest Publications

  • Targeting the Gut Microbiota‐Metabolism Axis: Novel Pharmacological Mechanisms and Translational Application Strategies for Oral Antidiabetic Drugs

    by Ruodi Yang, Shichao Zhang, Zishan Fu, Yufeng Yang, Qingfeng Wang, Ying Zhou, Jiaxin Li, Ruisi Yang, Shunyu Ning, Yan Shi, et al.

    Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic metabolic disease worldwide, and the clinical prevention and control situation is severe. Although the various antidiabetic drugs currently in clinical use can lower blood glucose levels through different mechanisms, there are significant differences in efficacy among individuals. Existing evidence suggests that differences in gut microbiota (GM) composition and metabolic function may be one of the key factors contributing to the heterogeneity in drug efficacy. Based on this, this review describes the physiological and pathological mechanisms of the GM‐metabolism axis and systematically reviews the modulatory effects of different classes of antidiabetic drugs on this axis and their underlying mechanisms. Available studies suggest that metformin, α‐glucosidase inhibitors, dipeptidyl peptidase‐4 inhibitors (DPP‐4i), sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), thiazolidinediones (TZDs), and oral glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may differentially affect GM composition and/or microbial metabolites, including short‐chain fatty acids (SCFAs), branched‐chain amino acids (BCAAs), and bile acids. These alterations may be associated with glucose homeostasis and insulin resistance through pathways involving GPR41/43, HDACs, AMPK, mTORC1/S6K1, FXR‐FGF15/19, and TGR5‐GLP‐1 signaling. By integrating clinical and mechanistic evidence, this review highlights the potential contribution of the GM‐metabolism axis to the glucose‐lowering effects of antidiabetic drugs. However, the quantity and confidence of evidence vary substantially across drug classes, and causal and clinical relevance requires further validation. These findings provide a basis for future research on personalized interventions for T2DM characterized by SCFA‐producing bacterial deficiency, BCAA overload, or dysregulated bile acid metabolism.

  • Regulation of Traditional Chinese Medicine Gut Microbiota Short-Chain Fatty Acid Axis in Type 2 Diabetes Management: A Review

    by Ruodi Yang, Ying Zhou, Yuhang Shen, Juntong Liu, Yan Shi, Yufeng Yang

    Type 2 diabetes mellitus (T2DM), a globally prevalent chronic metabolic disorder, imposes a significant worldwide public health burden. As a vital “microbial organ” within the human body, the balance of the gut microbiota (GM) structure and function is crucial for maintaining host metabolic health. Short-chain fatty acids (SCFAs), the metabolic products of GM, serve as key signaling molecules that play central roles in maintaining intestinal homeostasis, regulating systemic energy metabolism, and improving insulin sensitivity. Dysregulation of the “GM-SCFA axis” has emerged as a core pathological mechanism in the onset and progression of T2DM. Traditional Chinese Medicine (TCM) possesses unique advantages in T2DM treatment through its “holistic regulation and multi-targeted intervention,” which enables precise modulation of the GM-SCFA axis. This paper provides a systematic review of the pathological mechanisms by which dysregulation of the GM-SCFA axis induces T2DM, and specifically covers energy metabolism disorders, insulin resistance, intestinal barrier impairment, chronic low-grade inflammatory activation, abnormal bile acid metabolism regulation, and disrupted gut-pancreatic axis and gut-brain axis signaling. Using keywords such as TCM, GM, SCFAs, and T2DM, we conducted an extensive literature search across databases including PubMed, Google Scholar, and Web of Science for publications from the past decade. This systematic review examines the application of TCM in regulating the “GM-SCFA axis” from multiple perspectives: Chinese herbal compounds (e.g., Zuogui Jiangtang Qinggan Formula, Gegen Qinlian Decoction), Chinese patent medicines (e.g., Shouhui Tongbian Capsules, Compound Danshen Dripping Pills), single-herb Chinese medicines (e.g., Edgeworthia gardneri, Alpinia oxyphylla), single-component compounds from TCM (e.g., Cyclocarya paliurus polysaccharide, Achyranthes bidentata polysaccharide water-soluble 1), and other TCM therapies (e.g., tuina, acupuncture). This study aims to systematically explore the mechanisms by which dysregulation of the “GM-SCFA axis” induces T2DM while providing novel therapeutic strategies for T2DM prevention and treatment using TCM. It also seeks to establish scientific foundations for developing novel TCM intervention strategies targeting the “GM-SCFA axis” in T2DM management.


  • Open Access

    Food‐Herb Dual‐Function in Astragali Radix‐Poria‐Rheum: Network Pharmacology and Database Mining for Diabetic Kidney Disease Mechanisms Exploration

    by Meizi Wang, Weizhong Li, Qiong Cheng, Jiayu Sun, Cheng Cheng, Nana Wang, Ping Zhou, Min Zha, Yufeng Yang

    The growing demand for functional foods derived from medicinal‐edible homologous resources offers a promising strategy to address the chronic metabolic dysregulation underlying diabetic kidney disease (DKD), particularly in patients requiring long‐term pharmacological interventions. DKD, a metabolic disorder‐driven complication of diabetes, is characterized by chronic hyperglycemia, insulin resistance (IR), and systemic metabolic dysregulation, necessitating novel dietary approaches to complement conventional therapies. To systematically explore the therapeutic potential of medicinal‐edible homologous herbs in DKD management, this study retrieved clinical literature from the China National Knowledge Infrastructure (CNKI) database, focusing on traditional Chinese medicines (CHMs) with dual dietary and therapeutic functions. By integrating data mining techniques (frequency analysis, attribute‐flavor analysis, herb‐pair co‐occurrence networks, and cluster analysis) with expert clinical consensus, we prioritized the identification of core medicinal‐edible homologous combinations that align with DKD's metabolic pathology. This multi‐dimensional approach revealed Huangqi ( Astragali Radix ), Fuling ( Poria ), and Dahuang ( Rhei Radix et Rhizoma ) (Ast‐Por‐Rhe) as the most predictive herb combination, highlighting their synergistic role as functional food‐derived agents in mitigating DKD progression. Network pharmacology revealed that Ast‐Por‐Rhe's bioactive components (e.g., isorhamnetin, 7‐O‐methyleriodictyol) act as dual‐purpose nutrients and metabolic regulators, synergistically targeting 38 DKD‐associated genes. Functional enrichment analysis demonstrated Ast‐Por‐Rhe's capacity to restore metabolic homeostasis by alleviating IR through dephosphorylation modulation, while rectifying PI3K‐Akt signaling. In a streptozotocin (STZ)‐induced DKD rat model, Ast‐Por‐Rhe supplementation, as a functional food intervention, significantly mitigated renal metabolic dysfunction, evidenced by enhanced IRS1/PI3K/Akt activity, reduced lipid peroxidation, and improved renal fibrosis. These findings position Ast‐Por‐Rhe as a paradigm of medicinal‐edible homologous functional foods that counteract DKD progression through multi‐component synergy, specifically targeting IR‐driven metabolic perturbations. This study provides a translational roadmap for developing evidence‐based dietary strategies using bioactive food components, advancing the application of medicinal‐edible resources in metabolic disorder management.


  • Open Access

    A commentary on “Effect of parecoxib on postoperative delirium in patients with hyperlipidemia: a randomized, double-blind, single-center, superiority trial”

    by Ying Zhou, Juntong Liu, Yufeng Yang

    An abstract is unavailable. This article is available as a PDF only.

  • Open Access

    Fermentation: improvement of pharmacological effects and applications of botanical drugs

    by Xinxin Luo, Mosi Dong, Juntong Liu, Naifei Guo, Jing Li, Yan Shi, Yufeng Yang

    Fermentation is an important concoction technique for botanical drugs. Fermentation transforms and enhances the active ingredients of botanical drugs through specific microbiological processes, ultimately affecting their pharmacological effects. This review explores the use of fermented botanical drugs in areas such as anti-tumor, hypolipidemic, antioxidant, antimicrobial, cosmetology, and intestinal flora regulation. It elucidates the potential pharmacological mechanisms and discusses the benefits of fermentation technology for botanical drugs, including reducing toxic side effects, enhancing drug efficacy, and creating new active ingredients. This article also discussesdelves into the common strains and factors influencing the fermentation process, which are crucial for the successful transformation and enhancement of these drugs. Taken together, this study aimed to provide a reference point for further research and wider applications of botanical drug fermentation technology.


  • Top Cited Papers
    Open Access

    Flavonoids improve type 2 diabetes mellitus and its complications: a review

    by Xinrui Yi, Mosi Dong, Naifei Guo, Jinlong Tian, Ping Lei, Song Wang, Yufeng Yang, Yan Shi

    The prevalence of type 2 diabetes mellitus (T2DM) is increasing every year. Medications are currently the most common therapy for T2DM. However, these medications have certain adverse effects. In order to find safe and effective ways to improve this disease, researchers have discovered that some natural products can decrease blood sugar. Flavonoids are one of the most essential low molecular weight phenolic chemicals in the plant world, which widely exist in plant roots, stems, leaves, flowers, and fruits. They possess a variety of biological activities, including organ protection, hypoglycemic, lipid-lowering, anti-oxidative and anti-inflammatory effects. Some natural flavonoids ameliorate T2DM and its complications through anti-oxidation, anti-inflammatory action, glucose and lipid metabolism regulation, insulin resistance management, etc. Hence, this review aims at demonstrating the potential benefits of flavonoids in T2DM and its complications. This laid the foundation for the development of novel hypoglycemic medications from flavonoids.


  • Open Access

    Antitumor Effect of Si-Jun-Zi Decoction on SGC7901 Gastric Cancer Cells by CMTM2 Activation

    by Xiangnan Li, Wenna Chen, Lanying Miao, Hongwei Sun, Xia Gao, Shengnan Guo, Yueshi Zhang, Yufeng Yang, Junfu Guo

    The Si-Jun-Zi decoction (SJZ), a traditional Chinese medicine (TCM) formula, is used clinically against multiple malignancies, including gastric cancer (GC). In previous study, we have shown that SJZ plays an anticancer role in SGC7901 cell xenograft mice models. However, the underlying mechanisms are unclear. The objective of this study was to evaluate the effect and mechanism of SJZ on the proliferation, migration, invasion, and cancer stem cell-like properties of GC cells. High-throughput mRNA sequencing analysis was performed to investigate the global alterations in gene expression in xenograft tumors, and 56 significantly differentially expressed genes (43 upregulated and 13 downregulated genes) were identified between the SJZ group and the Model group totally. We focused on CMTM2, which was significantly increased after SJZ intervention, as a candidate target gene of SJZ. The results indicated that CMTM2 expression was elevated in SJZ-treated SGC7901 cells and knocking-down CMTM2 expression partially hampered the inhibitory effects of SJZ on the proliferation, migration, and invasion of GC cells. Moreover, SJZ treatment repressed the spheroid and colony-forming capacity in GC cells, accompanied by downregulation of stem cell markers including SOX2, NANOG, and CD44. CMTM2 knockdown antagonized the effects of SJZ on the cancer stem cell-like properties of SGC7901 cells. Thus, SJZ effectively suppressed the proliferation, migration, invasion, and cancer stem cell-like properties of GC cells in vitro by upregulating CMTM2 expression.